Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06157086
Other study ID # COMB157GFR06
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 21, 2023
Est. completion date January 31, 2026

Study information

Verified date April 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone +41613241111
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

SEPROS is a non-interventional study, based on primary data collection of MS adult patients who initiated ofatumumab as per neurologist practice and regardless of the study protocol.


Description:

This is a non-interventional, prospective (primary data), multicenter study conducted in metropolitan France. The primary objective of this study is to describe the quality of life of MS patients after initiation of treatment with ofatumumab. In order to form a representative sample of MS patients taking into account the terms of care in France, free or practicing neurologists in healthcare institutions (public or private) in different regions of France will be selected to participate in this study. The study will enroll adult patients with MS who initiated ofatumumab according to the physician's advice and independently of the study. Patients will be followed from initiation of ofatumumab either until (i) 12 months (± 1month) after initiation of ofatumumab (End of Study), or until (ii) discontinuation of treatment with ofatumumab prior to the completion of the 12-month follow-up (early termination); whichever occurs first (end of study or early termination).


Recruitment information / eligibility

Status Recruiting
Enrollment 294
Est. completion date January 31, 2026
Est. primary completion date January 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: 1. Male or female, 18 years of age or older 2. Patient with confirmed MS diagnosis 3. Patient initiating treatment with ofatumumab for the first time 4. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study 5. Patient not opposed to participation in this study 6. Patient willing and able to complete patient questionnaires Exclusion Criteria: 1. Patient treated with ofatumumab in the context of a clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ofatumumab
There is no treatment allocation. Participants with MS that initiated treatment with ofatumumabas per neurologist practice and regardless of the study protocol

Locations

Country Name City State
France Novartis Investigative Site Altkirch
France Novartis Investigative Site Dax Cedex
France Novartis Investigative Site Lyon
France Novartis Investigative Site Mulhouse
France Novartis Investigative Site Valence Cedex 9

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life - MUSIQoL questionnaire The primary objective of this non-interventional study is to describe the quality of life of adult patients with MS treated with ofatumumab in real life, in France, after 12 months of treatment with ofatumumab using the MUSIQoL Quality of Life Questionnaire.
The MuSiQoL measures MS-specific quality of life. It comprises 31 items covering 9 domains (activities of daily living, psychological well-being, symptoms, relationships with friends, relationships with family, relationships with the healthcare system, sentimental and sexual life, coping, and rejection). Each item is scored on a 6-point Likert scale. The score on each dimension is obtained by computing the mean of the item scores for that dimension. All dimension scores are linearly transformed to a 0-100 scale. The global index score is computed as the mean of the dimension scores. Higher scores represent higher quality of life.
12 months
Secondary Treatment satisfaction of patients treated with ofatumumab using TSQM 9 questionnaire TSQM -9 is a self-questionnaire used to assess patient satisfaction with their treatment. It is a validated questionnaire and a good predictor of compliance. It explores 4 dimensions of satisfaction (efficacy, side effects, simplicity and overall satisfaction), through 9 questions. Responses are expressed on a 7-point Likert scale to precisely capture the patient's point of view. The responses to the items are aggregated; thus, each dimension is noted between 0 (extremely dissatisfied) and 100 (extremely satisfied). 12 months
Secondary Impact of MS on professional activity using the 6-item WPAI questionnaire The WPAI measures absence, presence, decreased work productivity, and reduction in normal daily activities over the past 7 days. This self-questionnaire is non-specific for a disease and is developed in 6 questions. It works to calculate a health-related deterioration score, which combines the absence score and presence score. This deterioration score is rated between 0 and 1 where 1 corresponds to the maximum score, i.e. stopping work 12 months
Secondary Neurologist's decision criteria for initiating ofatumumab and patient involvement in the treatment choice For each patient included in the study, neurologist's decision criteria for ofatumumab initiation will be collected (i.e., patient characteristics and poor prognosis factors or reasons for treatment switch if applicable) as well as the involvement of the patient in the choice of treatment (yes or no) Baseline
Secondary Clinical evolution of Multiple sclerosis - EDSS score The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability. Scoring is based on an examination by a neurologist. 12 months
Secondary Clinical evolution of Multiple sclerosis - Number of patients with relapses Number of patients with relapses and number of patients with hospitalizations related to the relapse Up to 12 months
Secondary Number of patient adherent to ofatumumab from patient and practitioner perspectives Number of patient adherent to ofatumumab from patient and practitioner perspectives to be collected 12 months
Secondary Ofatumumab discontinuation Ofatumumab discontinuation by reason to be collected 12 months
Secondary Persistence on ofatumumab Patients still treated with ofatumumab at 6 and 12 months Month 6, Month 12
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Not yet recruiting NCT06053749 - An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Not yet recruiting NCT06450600 - Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education N/A
Recruiting NCT04926818 - Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Phase 3
Not yet recruiting NCT03624296 - Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study N/A
Terminated NCT04203498 - Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis Phase 3
Active, not recruiting NCT04602390 - Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis Phase 1
Completed NCT01804647 - Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
Terminated NCT04907305 - Next-Gen MS: Feed-forward PRO Data for MS Research
Active, not recruiting NCT03456206 - Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Completed NCT04705610 - Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography N/A
Completed NCT01366027 - PRISM Registry: Pseudobulbar Affect Registry Series N/A
Completed NCT03135249 - Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis Phase 4
Recruiting NCT05633875 - Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
Completed NCT02612935 - An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis N/A
Completed NCT02739542 - Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) Phase 4
Completed NCT03177655 - Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis N/A
Active, not recruiting NCT04777539 - Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis
Recruiting NCT02352194 - Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis N/A
Completed NCT02308579 - Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases N/A